Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.
Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refract...
Главные авторы: | Morel, A, Talbot, D |
---|---|
Формат: | Journal article |
Язык: | English |
Опубликовано: |
Dove Medical Press Ltd.
2010
|
Схожие документы
-
Second line therapy for metastatic urothelial carcinoma. Clinical case of vinflunine use
по: A. A. Gritskevich, и др.
Опубликовано: (2022-06-01) -
From clinical trials to the front line: Vinflunine for Treatment of UrothelialCell Carcinoma at the National Cancer Institute of Naples
по: GAETANO eFACCHINI, и др.
Опубликовано: (2016-05-01) -
Vinflunine in the treatment of bladder cancer
по: Mark Bachner, и др.
Опубликовано: (2008-11-01) -
A Prospective Study of I.V. Vinflunine in the Treatment of Patients with Advanced or Metastatic Urothelial Carcinoma after Failure of a Platinum-containing Regimen and Biomarker Correlates
по: Fatma M.A. Abouelkasem, и др.
Опубликовано: (2022-08-01) -
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)
по: Rodolfo Passalacqua, и др.
Опубликовано: (2017-07-01)